| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating …
Over the last 12 months, insiders at Enveric Biosciences, Inc. have bought $0 and sold $0 worth of Enveric Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Enveric Biosciences, Inc. have bought $2,140 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $2,140 was made by PASQUALONE FRANK (director) on 2023‑09‑15.
| 2023-09-15 | PASQUALONE FRANK | director | 1,000 0.043% | $2.14 | $2,140 | -59.50% | ||
| 2018-11-16 | Sale | Sikaria Lokesh | 10 percent owner | 100,000 1.778% | $0.30 | $29,550 | -1.72% | |
| 2018-11-16 | Sale | Sikaria Family 2008 Revocable Trust Dated 02/28/2008 | 10 percent owner | 100,000 1.778% | $0.30 | $29,550 | -1.72% | |
| 2018-11-16 | Sale | Sikaria Chanda | 10 percent owner | 100,000 1.778% | $0.30 | $29,550 | -1.72% | |
| 2018-11-16 | Sale | Lokesh Sikaria Trust Dated 12/14/2012 | 10 percent owner | 100,000 1.778% | $0.30 | $29,550 | -1.72% | |
| 2018-07-17 | Sale | Devanur Giri | 10 percent owner | 100,000 2.4059% | $2.27 | $226,630 | -81.13% | |
| 2018-06-07 | Sale | Devanur Giri | 10 percent owner | 329,357 10.2759% | $2.01 | $661,316 | -76.54% | |
| 2017-11-17 | Eberwein Jeffrey E. | 100,000 2.8873% | $4.12 | $411,500 | -68.05% | |||
| 2017-11-17 | Devanur Giri | President & CEO | 12,121 0.35% | $4.12 | $49,878 | -68.05% | ||
| 2017-11-17 | Rai Dhruwa N | director | 145,450 4.1995% | $4.12 | $598,527 | -68.05% | ||
| 2017-10-30 | Eberwein Jeffrey E. | 1,303 0.0319% | $6.50 | $8,469 | -78.00% | |||
| 2017-10-27 | Eberwein Jeffrey E. | 2,500 0.0612% | $6.50 | $16,250 | -76.92% | |||
| 2017-09-06 | Eberwein Jeffrey E. | 7,500 0.2039% | $6.50 | $48,750 | -75.69% | |||
| 2017-08-21 | Eberwein Jeffrey E. | 2,604 0.0672% | $6.50 | $16,924 | -76.93% | |||
| 2017-03-30 | Eberwein Jeffrey E. | 223 0.0063% | $6.51 | $1,452 | -38.86% | |||
| 2017-02-10 | Eberwein Jeffrey E. | 434 0.0123% | $6.51 | $2,825 | -36.71% | |||
| 2017-01-23 | Eberwein Jeffrey E. | 2,130 0.0605% | $6.51 | $13,866 | -36.71% | |||
| 2017-01-18 | Eberwein Jeffrey E. | 10,000 0.2839% | $6.51 | $65,100 | -36.71% | |||
| 2016-12-30 | Eberwein Jeffrey E. | 40 0.0012% | $6.51 | $260 | -52.38% | |||
| 2016-12-29 | Eberwein Jeffrey E. | 706 0.0203% | $6.51 | $4,596 |
| Increased Positions | 9 | +112.5% | 4,001 | +13.2% |
| Decreased Positions | 4 | -50% | 10,148 | -33.47% |
| New Positions | 5 | New | 2,280 | New |
| Sold Out Positions | 2 | Sold Out | 4,265 | Sold Out |
| Total Postitions | 13 | +62.5% | 24,171 | -20.28% |
| Advisorshares Investments Llc | $62.00 | 1.7% | 16,973 | +8,333 | +96.45% | 2025-09-30 |
| Ubs Group Ag | $32.00 | 0.88% | 8,777 | +6,499 | +285.29% | 2025-09-30 |
| Geode Capital Management, Llc | $9.00 | 0.24% | 2,376 | +29 | +1.24% | 2025-09-30 |
| Citadel Advisors Llc | $7.00 | 0.19% | 1,889 | +1,889 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.02% | 201 | -45 | -18.29% | 2025-09-30 |
| Blackrock, Inc. | $0 | 0.01% | 50 | 0 | 0% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | 0.01% | 50 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | 0% | 2 | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $0 | 0% | 0 | -1,085 | Sold Out | 2025-09-30 |
| Renaissance Technologies Llc | $0 | 0% | 0 | -3,084 | Sold Out | 2025-09-30 |